Company Overview of ContraVir Pharmaceuticals, Inc.
ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company. It primarily focuses on the clinical development of FV-100, an orally available nucleoside analogue prodrug of CF-1743 for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or chickenpox. The company was founded in 2013 and is headquartered in Edison, New Jersey. ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV) operates independently of Synergy Pharmaceuticals, Inc. as of December 11, 2014.
399 Thornall Street
Edison, NJ 08837
Founded in 2013
Key Executives for ContraVir Pharmaceuticals, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $86.2K
Chief Financial Officer
Total Annual Compensation: $4.9K
Compensation as of Fiscal Year 2014.
ContraVir Pharmaceuticals, Inc. Key Developments
ContraVir Pharmaceuticals, Inc. Appoints Nathaniel Katz, M.D. as Chairman of Scientific Advisory Board
Dec 16 14
ContraVir Pharmaceuticals, Inc. announced the formation of a Scientific Advisory Board to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D. has joined ContraVir as Chairman of the newly formed SAB. Nathaniel P. Katz, M.D., M.S., is President and Chief Executive Officer of Analgesic Solutions.
ContraVir Pharmaceuticals, Inc. Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
Dec 9 14
ContraVir Pharmaceuticals, Inc. announced that it has initiated a pharmacokinetic (PK) study of FV-100, the company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development. FV-100 is a fast acting, low dose, once-daily oral antiviral agent being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus.Â In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain, known as post-herpetic neuralgia, or PHN. In addition to the current PK trial, ContraVir has completed planning a larger clinical study of FV-100 to confirm the previous favorable efficacy and safety results.Â The study is designed to measure the efficacy of FV-100 for treating Shingles and associated PHN, as measured by the incidence of clinically meaningful pain at the end of the follow-up period, as well as determine the best dose and regimen of treatment.
Contravir Pharmaceuticals, Inc. Proposes Amendment to it's Certificate of Incorporation
Oct 27 14
ContraVir Pharmaceuticals, Inc. announced that it will propose for shareholders approval at its AGM, to be held on December 02, 2014, to approve an amendment to the Company's Certificate of Incorporation to authorize the Board of Directors of the company to effect a reverse stock split of the company's common stock by a ratio of not less than 1-for-2 and not more than 1-for-5, with the Board of the company having the discretion as to whether or not the reverse split is to be effected at any time prior to the first anniversary date of this meeting of stockholders, and with the exact ratio of any reverse split to be set at a whole number within the above range as determined by the company's Board in its discretion (the Reverse Split Proposal).
Similar Private Companies By Industry
Recent Private Companies Transactions
October 14, 2014
February 4, 2014